Chemical formula: C₁₆H₂₁NO₂ Molecular mass: 259.343 g/mol PubChem compound: 4946
Propranolol is a competitive antagonist at both beta, and beta2-adrenoceptor, but has membrane stabilising activity at concentrations exceeding 1-3mg/litre, though such concentrations are rarely achieved during oral therapy. Competitive beta-blockade has been demonstrated in man by a parallel shift to the right in the dose-heart rate response curve to beta-agonists such as isoprenaline.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
ATC code | Group title | Classification |
---|---|---|
C07AA05 | Propranolol | C Cardiovascular system → C07 Beta blocking agents → C07A Beta blocking agents → C07AA Beta blocking agents, non-selective |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
Title | Information Source | Document Type | |
---|---|---|---|
PROPANOLOL Film-coated tablets | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
HEMANGIOL Oral solution | European Medicines Agency (EU) | MPI, EU: SmPC |
Propranolol is an active ingredient of these brands:
United States (US)
Brazil (BR)
Croatia (HR)
Cyprus (CY)Estonia (EE)
Finland (FI)Germany (DE)Hong Kong (HK)Ireland (IE)
Lithuania (LT)
Mexico (MX)
Netherlands (NL)
New Zealand (NZ)
Nigeria (NG)
Poland (PL)
Romania (RO)
South Africa (ZA)Tunisia (TN)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.